ライフサイエンスコーパス: pyrimethamine

1 unate-amodiaquine or amodiaquine-sulfadoxine-pyrimethamine.

2 sed efficacy of amodiaquine plus sulfadoxine-pyrimethamine.

3 hydrophobic antifols such as trimetrexate or pyrimethamine.

4 dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine.

5 uch as chloroquine, quinine, and sulfadoxine-pyrimethamine.

6 enotype and clinical or in vitro response to pyrimethamine.

7 modiaquine, or amodiaquine plus sulphadoxine-pyrimethamine.

8 7 participants assigned to sulfadoxine\#8211;pyrimethamine.

9 nation therapy, chloroquine, and sulfadoxine-pyrimethamine.

10 50 concentrations of mefloquine, quinine and pyrimethamine.

11 ioration of the effectiveness of sulfadoxine-pyrimethamine.

12 four of 138 (3%) on amodiaquine/sulfadoxine/pyrimethamine.

13 lus placebo; or amodiaquine plus sulfadoxine/pyrimethamine.

14 tance to cycloguanil but hypersensitivity to pyrimethamine.

15 de range of sensitivities to chloroquine and pyrimethamine.

16 ) coding sequences that confer resistance to pyrimethamine.

17 ittent preventive treatment with sulfadoxine-pyrimethamine.

18 s: mefloquine, chloroquine, doxycycline, and pyrimethamine.

19 ely reduced by an anti-STAT3 treatment using pyrimethamine.

20 on cassette were retrieved by selection with pyrimethamine.

21 th inhibition IC50 values lower than that of pyrimethamine (0.4 microM) with 14 compounds below 0.1 m

22 in blocks of 16 to sulfadoxine (250 mg) plus pyrimethamine (12.5 mg; n=319 in moderate-transmission a

23 125 [35%]) than with amodiaquine+sulfadoxine-pyrimethamine (12/129 [9%]; risk difference 26% [95% CI

24 ent over 28 days for amodiaquine+sulfadoxine-pyrimethamine (17/129 [13%]) and amodiaquine+artesunate

25 1.1%-32.1%) for amodiaquine plus sulfadoxine-pyrimethamine, 17.4% (95% CI, 13.1%-23.1%) for amodiaqui

26 quine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimeth

27 ere randomly assigned to receive sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, and 1.25 mg/kg pyri

28 ficantly higher with chloroquine+sulfadoxine-pyrimethamine (44/125 [35%]) than with amodiaquine+sulfa

29 mine (90%) than those receiving sulphadoxine-pyrimethamine (48%) or no antimalarial drugs (34%; p<0.0

30 In order to identify structural features of pyrimethamine (5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-

31 97 of 476 (20%) for amodiaquine+sulfadoxine-pyrimethamine, 54 of 491 (11%) for amodiaquine+artesunat

32 ts aged 2-11 months, but neither sulfadoxine-pyrimethamine (-6.7%, -45.9 to 22.0) nor chlorproguanil-

33 tal care, and randomly assigned sulphadoxine-pyrimethamine (640) or placebo (624).

34 quine (86%) or amodiaquine plus sulphadoxine-pyrimethamine (90%) than those receiving sulphadoxine-py

35 When used in combination with pyrimethamine, a DHFR inhibitor, a synergistic effect wa

36 -dapsone was less effective than sulfadoxine-pyrimethamine (adjusted odds ratio [OR], 6.4; 95% confid

37 36-66, p<0.0001) compared with sulfadoxine/ pyrimethamine alone and by 37% (12-54, p=0.007) compared

38 ignificantly more effective than sulfadoxine/pyrimethamine alone in children aged younger than 5 year

39 ne alone or in combination with sulphadoxine-pyrimethamine, although associated with minor side-effec

40 tion therapies (amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate, or artemethe

41 We compared chloroquine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, an

42 the women assigned chloroquine, sulphadoxine-pyrimethamine, amodiaquine, and amodiaquine plus sulphad

43 Sulfadoxine/pyrimethamine, amodiaquine, and amodiaquine/sulfadoxine/

44 We compared the efficacy of sulfadoxine/pyrimethamine, amodiaquine, and an amodiaquine/sulfadoxi

45 randomly assigned chloroquine, sulphadoxine-pyrimethamine, amodiaquine, or amodiaquine plus sulphado

46 cation with treatment studies of sulfadoxine-pyrimethamine among symptomatic children.

47 fected cells with the toxoplasmastatic drugs pyrimethamine and 6-thioxanthine prior to LPS stimulatio

48 dy a high level of resistance to sulfadoxine-pyrimethamine and amodiaquine.

49 e alternative treatments include sulfadoxine/pyrimethamine and amodiaquine.

50 high prevalence of resistance to sulfadoxine-pyrimethamine and chloroquine.

51 ind, placebo-controlled trial of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment for u

52 he dihydrofolate reductase (DHFR) inhibitors pyrimethamine and cycloguanil have sparked renewed inter

53 get of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of

54 e reductase (DHFR) to two related inhibitors-pyrimethamine and cycloguanil-across a breadth of drug c

55 been associated with in vitro resistance to pyrimethamine and cycloguanil.

56 with either chloroquine or sulfadoxine\#8211;pyrimethamine and followed for 28 days to assess the ant

57 a new marker that confers both resistance to pyrimethamine and green fluorescent protein-based fluore

58 susceptibly to the non-classical antifolates pyrimethamine and nolatrexed.

59 Treatment of malaria with sulfadoxine/pyrimethamine and of presumed bacterial infections with

60 imalarials, such as Chloroquine, Sulfadoxine-Pyrimethamine and oral Artesunate monotherapy.

61 ed until delivery with regular monitoring of pyrimethamine and sulfadiazine concentration in maternal

62 groups preferring to use the combination of pyrimethamine and sulfadiazine.

63 and dhps genes respectively associated with pyrimethamine and sulfadoxine resistance.

64 teroate synthase (DHPS) confer resistance to pyrimethamine and sulfadoxine, respectively.

65 ions in enzymes targeted by the antifolates, pyrimethamine and sulphadoxine.

66 oses of the clinical antimalarial inhibitors pyrimethamine and tetracycline and observed differential

67 tive treatment with two doses of sulfadoxine-pyrimethamine and the use of insecticide-treated nets.

68 um parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days.

69 intermittent preventive therapy (sulfadoxine-pyrimethamine) and insecticide-treated mosquito nets are

70 oxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, and amodiaquine+artesunate for treatment

71 led trial comparing chloroquine, sulfadoxine-pyrimethamine, and chlorproguanil-dapsone for the treatm

72 ne than among those who received sulfadoxine-pyrimethamine, and monthly treatment with dihydroartemis

73 ve pharmaceutical ingredients, sulfalene and pyrimethamine, and NQR analysis revealed spectral differ

74 axis with the combination of sulfadoxine and pyrimethamine, and treatment, as needed.

75 ne alone or in combination with sulphadoxine-pyrimethamine as alternative regimens.

76 n, we identified the anti-parasitic compound pyrimethamine as an inhibitor of STAT3 function.

77 ed as a potential alternative to sulfadoxine-pyrimethamine as intermittent preventive treatment again

78 in an area of high resistance to sulfadoxine-pyrimethamine at sites of moderate (n=1280 infants enrol

79 Administration of sulfadoxine-pyrimethamine at times of vaccination-intermittent preve

80 e and received only one dose of sulphadoxine-pyrimethamine benefited significantly from the intervent

81 in T. gondii) probably confers resistance to pyrimethamine by affecting critical interactions in the

82 In contrast, inhibition of MATE1 with pyrimethamine caused accumulation of metformin in the li

83 amodiaquine, and an amodiaquine/sulfadoxine/pyrimethamine combination for treatment of uncomplicated

84 The amodiaquine/sulfadoxine/pyrimethamine combination was the most effective, and co

85 ildren <5 years old treated with sulfadoxine/pyrimethamine, cotrimoxazole, or no antimicrobial agent

86 Treatment with pyrimethamine decreases cell proliferation in human ADPK

87 The triazenyl-pyrimethamine derivative 3a (TAB), a potent and selectiv

88 IPTi with sulfadoxine-pyrimethamine did not have a clinically significant effe

89 INTERPRETATION: IPTi with sulfadoxine-pyrimethamine does not affect serological responses to E

90 Nine trials of IPT with sulfadoxine-pyrimethamine during pregnancy in Africa were identified

91 red 2-dose with monthly IPT with sulfadoxine-pyrimethamine during pregnancy.

92 egnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children

93 om two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third trimesters, bu

94 uail eggs were found to contain florfenicol, pyrimethamine, estrone and 17beta-estradiol at levels fr

95 in which 1 of 4 treatments with sulfadoxine-pyrimethamine fail in children by day 14, the 2-dose IPT

96 Sulfadoxine/pyrimethamine (Fansidar) is widely used in Africa for tr

97 re treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplicated malaria

98 sing alternative drug to replace sulfadoxine-pyrimethamine for intermittent preventive treatment.

99 uine with the combination of sulfadoxine and pyrimethamine for the treatment of malaria.

100 da were treated with amodiaquine+sulfadoxine-pyrimethamine for uncomplicated malaria.

101 ittent preventive treatment with sulfadoxine-pyrimethamine group (15 [3%] of 457 women vs 47 [10%] of

102 raquine group (9.2%) than in the sulfadoxine-pyrimethamine group (18.6%, P=0.05) or the three-dose di

103 gnificantly more frequent in the sulfadoxine/pyrimethamine group (38 of 215, 18%) compared with eithe

104 was significantly higher in the sulfadoxine-pyrimethamine group (41 episodes over 43.0 person-years

105 was significantly higher in the sulfadoxine-pyrimethamine group (50.0%) than in the three-dose dihyd

106 30 (5.3%) of 567 women in the sulphadoxine-pyrimethamine group and 199 (35.3%) of 564 in the placeb

107 By day 14, only 1 patient in the sulfadoxine-pyrimethamine group had parasites.

108 nce of parasitemia (40.5% in the sulfadoxine-pyrimethamine group vs. 16.6% in the three-dose dihydroa

109 5 of 290 patients (1.7%) in the sulfadoxine-pyrimethamine group, and 27 of 272 patients (9.9%) in th

110 , even in eastern and southern Africa, where pyrimethamine has been intensively used.

111 Sulfadoxine-pyrimethamine has been widely used as first-line therapy

112 IPTi with sulfadoxine-pyrimethamine has no benefit in areas of very high resis

113 ce to the antifolate combination sulfadoxine-pyrimethamine have a common origin.

114 Antifolate antimalarials, such as pyrimethamine, have experienced a dramatic reduction in

115 y (IC50 = 0.1-0.5 microM) similar to that of pyrimethamine (IC50 = 0.69 microM), a standard clinical

116 randomly assigned to treatment (sulfadoxine-pyrimethamine in combination with amodiaquine or dual pl

117 and susceptible parasites are exacerbated by pyrimethamine in mice.

118 finity)) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum women, although

119 intermittent treatment doses of sulphadoxine-pyrimethamine in preventing malaria and severe anaemia i

120 ittent preventive treatment with sulfadoxine-pyrimethamine in the context of high sulfadoxine-pyrimet

121 preventive treatment (IPT) with sulphadoxine-pyrimethamine in vulnerable populations reduces malaria

122 ia prevention (ITNs or IPTp with sulfadoxine-pyrimethamine) in pregnancy and birth outcomes, includin

123 individuals (934 placebo and 970 sulfadoxine-pyrimethamine) in the study.

124 effectiveness of daily CMX with sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP)

125 chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermittent treatment), and to improve ma

126 ittent preventive treatment with sulfadoxine-pyrimethamine, intermittent preventive treatment with di

127 ittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) during pregnancy.

128 eventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in su

129 ttent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP).

130 entive therapy in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP).

131 (IPTp-SP3+) versus two doses of sulfadoxine-pyrimethamine (IPTp-SP2).

132 ciparum to the antimalarial drug sulfadoxine-pyrimethamine is a result of extremely rare mutations th

133 tent presumptive treatment with sulphadoxine-pyrimethamine is an effective, practicable strategy to d

134 Pyrimethamine is capable of producing a significant redu

135 The target enzyme of pyrimethamine is dihydrofolate reductase (DHFR), but lit

136 Increasing resistance to sulfadoxine-pyrimethamine is leading to a decline in its effectivene

137 Resistance to sulfadoxine-pyrimethamine is now increasing, especially in southeast

138 INTERPRETATION: Pyrimethamine is safe and well tolerated in ALS.

139 Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention o

140 Glyphosate in combination with pyrimethamine limited T. gondii infection in mice.

141 This study investigated whether pyrimethamine lowered SOD1 levels in the cerebrospinal f

142 A previous phase 1 trial showed pyrimethamine lowers SOD1 levels in leukocytes in patien

143 We propose that clinical dosages of pyrimethamine may have historically been too low to sele

144 ve therapy during pregnancy with sulfadoxine-pyrimethamine monotherapy.

145 modiaquine (n=270), amodiaquine +sulfadoxine-pyrimethamine (n=507), or amodiaquine+artesunate (n=515)

146 ittent preventive treatment with sulfadoxine-pyrimethamine (n=515); 1368 (88%) women comprised the in

147 ntry to replace chloroquine with sulfadoxine-pyrimethamine nationwide in response to high rates of ch

148 with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed.

149 in 13 of 131 (10%) patients on sulfadoxine/ pyrimethamine, nine of 131 (7%) on amodiaquine, and four

150 Data on the efficacy of IPT with sulfadoxine-pyrimethamine on placental and peripheral malaria, birth

151 fect of increasing resistance to sulfadoxine-pyrimethamine on the efficacy of IPT during pregnancy in

152 Combinations of amodiaquine and sulfadoxine-pyrimethamine or artesunate were significantly more effi

153 xual parasites more rapidly than sulfadoxine-pyrimethamine or chlorproguanil-dapsone did.

154 e investigated whether IPTi with sulfadoxine-pyrimethamine or other antimalarial drug combinations ad

155 f an adverse effect of IPTi with sulfadoxine-pyrimethamine or other antimalarial drugs on the proport

156 nd 15, respectively) than in the sulfadoxine-pyrimethamine or placebo groups (eight deaths per group;

157 STAT3 and that blocking STAT3 signaling with pyrimethamine or similar drugs may be an attractive ther

158 e of artesunate plus one dose of sulfadoxine-pyrimethamine or two placebos on three occasions during

159 quine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine; or amodiaquine and artesunate (4 mg/kg da

160 Unlike pyrimethamine, P218 binds both wild-type and mutant PfDH

161 us did not show any significant influence on pyrimethamine pharmacokinetics.

162 o involving atropisomerism about the pivotal pyrimethamine-phenyl bond.

163 mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) was more effective

164 Sulfadoxine/pyrimethamine plus amodiaquine could be used as an inexp

165 5, 18%) compared with either the sulfadoxine/pyrimethamine plus amodiaquine group (two of 164, 1%; p<

166 28 and 42 days, patients in the sulfadoxine/pyrimethamine plus amodiaquine group were significantly

167 Overall, sulfadoxine/pyrimethamine plus amodiaquine reduced the rate of subse

168 up (two of 164, 1%; p<0.0001) or sulfadoxine/pyrimethamine plus artesunate group (one of 198, 1%; p<0

169 % (12-54, p=0.007) compared with sulfadoxine/pyrimethamine plus artesunate.

170 receive 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine plus either placebo, 25 mg/kg amodiaquine,

171 hamine (25 mg/kg sulfadoxine, and 1.25 mg/kg pyrimethamine) plus placebo; amodiaquine (25 mg/kg) plus

172 Pyrimethamine pressure is not necessary for maintaining

173 Under pyrimethamine pressure, transformed parasites were obtai

174 Pyrimethamine produces dose-dependent SOD1 reduction in

175 aimiri boliviensis monkeys infected with the pyrimethamine (Pyr)-susceptible Chesson strain with a ZF

176 domly assigned participants to a sulfadoxine-pyrimethamine regimen (106 participants), a three-dose d

177 n by day 14, the 2-dose IPT with sulfadoxine-pyrimethamine regimen continues to provide substantial b

178 onsistent across a wide range of sulfadoxine-pyrimethamine resistance (0% to 96% dihydropteroate-synt

179 methamine in the context of high sulfadoxine-pyrimethamine resistance and malaria transmission.

180 hich has experienced sustained selection for pyrimethamine resistance at the dihydrofolate reductase

181 The spread of high-level pyrimethamine resistance in Africa threatens to curtail

182 We report that increases in gch1 CN alter pyrimethamine resistance in most parasites lines.

183 Pyrimethamine resistance in the malaria parasite Plasmod

184 This allele also conferred high levels of pyrimethamine resistance in vitro.

185 scents or women in Uganda, where sulfadoxine-pyrimethamine resistance is widespread.

186 The effect did not vary by sulfadoxine-pyrimethamine resistance levels (range, 19%-26%).

187 ng that malaria parasites bearing high-level pyrimethamine resistance originally arrived in Africa fr

188 CI, 19-205 g) over the range of sulfadoxine-pyrimethamine resistance tested (8%-39%).

189 le evolutionary pathways in the evolution of pyrimethamine resistance using an approach in which all

190 Sulfadoxine-pyrimethamine resistance was defined as the proportion o

191 The movement by the dhfr alleles (pyrimethamine resistance) preceded that of the dhps alle

192 e simulated realizations of the evolution of pyrimethamine resistance.

193 th high malaria transmission and sulfadoxine-pyrimethamine resistance.

194 4 key amino acid replacements implicated in pyrimethamine resistance: N51I, C59R, S108N, and I164L.

195 In order to directly assess the costs of pyrimethamine-resistance in vivo, we have carried out co

196 will complement transformation with existing pyrimethamine-resistance markers in functional studies o

197 d in vivo, which may explain why this highly pyrimethamine-resistant allele has not been observed in

198 t-expression system to identify rare, highly pyrimethamine-resistant alleles of dhfr in isolates from

199 rocytic development of both chloroquine- and pyrimethamine-resistant P. falciparum strains with poten

200 kb region with extremely low polymorphism in pyrimethamine-resistant parasites.

201 Molecular assays for monitoring sulfadoxine-pyrimethamine-resistant Plasmodium falciparum have not b

202 odiaquine, and amodiaquine plus sulphadoxine-pyrimethamine, respectively (p<0.0001).

203 cific alleles and the failure of sulfadoxine/pyrimethamine (S/P) to clear the erythrocytic stages of

204 ased risk of clinical failure of sulfadoxine-pyrimethamine (S/P).

205 e if changes in gch1 expression alone modify pyrimethamine sensitivity, we manipulated gch1 CN in sev

206 imethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine, single dose); amodiaquine (25 mg/kg over

207 eated with chloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) plus SP were tes

208 atment (IPTp) with two doses of sulphadoxine-pyrimethamine (SP) and insecticide-treated-nets (ITNs) i

209 ficacy of this drug with that of sulfadoxine-pyrimethamine (SP) as treatment for uncomplicated falcip

210 (IPTi) is the administration of sulfadoxine-pyrimethamine (SP) at 2, 3, and 9 months of age to preve

211 ent during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malaria parasitem

212 tudied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments am

213 However, sulfadoxine-pyrimethamine (SP) efficacy is threatened by high-level

214 istance to the antimalarial drug sulfadoxine-pyrimethamine (SP) emerged in Plasmodium falciparum from

215 anization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment

216 sites resistant to the IPTp drug sulfadoxine-pyrimethamine (SP) have emerged worldwide, and infection

217 piperaquine (DP) was superior to sulfadoxine-pyrimethamine (SP) in preventing maternal and placental

218 s paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in recommended antimalarial regimens.

219 Pfdhfr and Pfdhps have rendered sulfadoxine-pyrimethamine (SP) ineffective for malaria treatment in

220 otrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp

221 ugs such as chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) is a major global health threat.

222 Sulfadoxine-pyrimethamine (SP) is among the most commonly used antim

223 ent during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against malaria but may

224 eatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention

225 Sulfadoxine-pyrimethamine (SP) is used throughout Africa for intermi

226 ts and received a single dose of sulfadoxine-pyrimethamine (SP) on enrollment, followed by either int

227 laria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), given each mon

228 Tp comparing the standard 2-dose sulfadoxine-pyrimethamine (SP) regimen with monthly IPTp among a coh

229 ciated with chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance and the microsatellite loc

230 Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, mon

231 In 2007, Malawi replaced sulfadoxine-pyrimethamine (SP) with an artemisinin-based combination

232 e to no chemoprevention, monthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole

233 lm of blood and was treated with sulfadoxine/pyrimethamine (SP), in accordance with national policy.

234 d for uncomplicated malaria with sulfadoxine-pyrimethamine (SP), SP + amodiaquine (AQ), or SP + artes

235 malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recommended for i

236 lacebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP), SP+amodiaquine, SP+piperaquine, SP+c

237 to concerns about resistance to sulphadoxine-pyrimethamine (SP), the only drug currently recommended

238 times inadvertently treated with sulfadoxine-pyrimethamine (SP).

239 g simultaneous administration of sulfadoxine-pyrimethamine (SP-IPTi) with immunizations, we measured

240 By contrast, resistance to sulphadoxine-pyrimethamine (SPR) has emerged during an era of molecul

241 ittent preventive treatment with sulfadoxine-pyrimethamine strategy recommended by WHO is threatened

242 In a control sulfadoxine-pyrimethamine study, the prevalence of ms4760-1 was simi

243 he pregnant woman until week 16, followed by pyrimethamine, sulfadiazine, and folinic acid for at lea

244 at least 4 weeks of combination therapy with pyrimethamine, sulfadiazine, and folinic acid independen

245 udy raises questions about any policy to use pyrimethamine-sulfadoxine alone as the first-line treatm

246 ted with standard regimens of chloroquine or pyrimethamine-sulfadoxine alone or in combination with 1

247 was 8-fold higher in the group that received pyrimethamine-sulfadoxine alone.

248 ransmission was lowest in those who received pyrimethamine-sulfadoxine and 3 doses of artesunate, and

249 , Gly437, and Glu540 of DHPS was selected by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone

250 efficacy of chloroquine, and the combination pyrimethamine-sulfadoxine is the most commonly chosen al

251 fore and 3 weeks after treatment with either pyrimethamine-sulfadoxine or chlorproguanil-dapsone was

252 tation at DHPS 540 correlated with increased pyrimethamine-sulfadoxine resistance (P < .05).

253 4 and DHPS 581 were common in Bolivia, where pyrimethamine-sulfadoxine resistance is widespread, but

254 dihydropteroate synthase (DHPS) and clinical pyrimethamine-sulfadoxine resistance, polymerase chain r

255 opment of molecular surveillance methods for pyrimethamine-sulfadoxine resistance.

256 in four countries with increasing levels of pyrimethamine-sulfadoxine resistance: Mali, Kenya, Malaw

257 timalarial agents to replace chloroquine and pyrimethamine/sulfadoxine threatens efforts to control t

258 ed the synergy of the antifolate combination pyrimethamine/sulfadoxine.

259 The antifolate combination pyrimethamine/sulphadoxine (PYR/SDX; Fansidar) is freque

260 The declining efficacy of chloroquine and pyrimethamine/sulphadoxine in the treatment of human mal

261 ich enabled teachers to dispense sulfadoxine-pyrimethamine tablets according to national guidelines.

262 m falciparum to chloroquine and sulphadoxine-pyrimethamine threatens the use of these drugs for malar

263 trials compared 2-dose IPT with sulfadoxine-pyrimethamine to case management or placebo in women dur

264 rmittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is use

265 or coadministration of IPTi with sulfadoxine-pyrimethamine to infants at the time of the second and t

266 aken to determine the safety and efficacy of pyrimethamine to lower SOD1 levels in the CSF in fALS/SO

267 ttent preventive treatment with sulphadoxine-pyrimethamine to pregnant women (IPTp-SP) through antena

268 Expanding use of sulfadoxine/pyrimethamine to treat chloroquine-resistant malaria may

269 In sulfadoxine/pyrimethamine-treated children, the proportion colonized

270 e was no evidence of transcript induction in pyrimethamine-treated parasites.

271 le mutant") were associated with sulfadoxine-pyrimethamine treatment failure but not with chlorprogua

272 in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodia

273 ded among factors that determine sulfadoxine-pyrimethamine treatment outcome.

274 associated with chloroquine or sulphadoxine-pyrimethamine treatment, attention has turned to the few

275 HIV infection on the response to sulfadoxine-pyrimethamine treatment.

276 100), and the efficacy of sulfadoxine\#8211;pyrimethamine was 21% (95% CI, 13 to 30).

277 therapy with 3 or more doses of sulfadoxine-pyrimethamine was associated with a higher birth weight

278 eatment failure with amodiaquine+sulfadoxine-pyrimethamine was balanced by a lower risk of new infect

279 m 2368 children from sites where sulfadoxine-pyrimethamine was compared with placebo were analysed fo

280 Sulfadoxine-pyrimethamine was first introduced for treatment of mala

281 Efficacy of IPT with sulfadoxine-pyrimethamine was lower among women using insecticide-tr

282 Pyrimethamine was measured in plasma and CSF.

283 minant of treatment outcome with sulfadoxine-pyrimethamine was retrospectively studied in young child

284 Amodiaquine/sulfadoxine/pyrimethamine was significantly more effective than sulf

285 eatment failure with chloroquine+sulfadoxine-pyrimethamine was unacceptably high.

286 ne, amodiaquine, and amodiaquine/sulfadoxine/pyrimethamine were all effective for treatment of uncomp

287 The pharmacokinetics of sulfadoxine and pyrimethamine were compared between these groups.

288 Chloroquine and sulfadoxine-pyrimethamine were equivalent in efficacy at day 28 (adj

289 blinded clinical trial comparing sulfadoxine-pyrimethamine with mefloquine IPTp.

290 ly the most effective, is the combination of pyrimethamine with sulfadiazine and folinic acid.

291 Treatment with lower and higher doses of pyrimethamine with sulfadizine improved outcomes relativ